Clinical Trial Update: A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) [Phase 3]

View source ↗

Summary

Phase 3 trial update for subcutaneous immunoglobulin 20% (IGSC, 20%) in Japanese participants with primary immunodeficiency diseases completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• IGSC, 20% (Immune Globulin Subcutaneous (Human) 20%) (immune globulin)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED | Results posted: 2024-03-22